Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT01198067
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 267
- Registration Number
- NCT01178281
- Locations
- 🇵🇱
Centralny Szpital Kliniczny MSWiA, Warsaw, Poland
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇧🇪Universitaire Ziekenhuis Leuven Gathuisberg, Leuven, Belgium
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 71
- Registration Number
- NCT01177735
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, United States
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 121
- Registration Number
- NCT01159574
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Steven P. Treon, MD, PhD
- Target Recruit Count
- 7
- Registration Number
- NCT01078974
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 84
- Registration Number
- NCT01053949
- Locations
- 🇫🇷
CHRU-Hôpital Sud, avenue Laennec,, Amiens, France
🇫🇷Hématologie, Hôpital Avicenne, Bobigny, France
🇫🇷Hématologie, CHRU, Hôpital A.Michallon, Grenoble, France
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 103
- Registration Number
- NCT00949364
- Locations
- 🇩🇪
Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪Klinikum der Johann Goethe-Universität Frankfurt, Frankfurt, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Germany
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 259
- Registration Number
- NCT00833833
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 7
- Registration Number
- NCT00717522
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 378
- Registration Number
- NCT00558896
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.